Related Experiment Videos

Pharmacogenomic assessment of treatment options in gestational diabetes

T Ort1, M Voss, A Lichtmacher

  • 1CuraGen Corporation, Branford, CT, USA.

The Pharmacogenomics Journal
|September 28, 2005
PubMed

Insights

Gene expression analysis reveals insulin treatment is more effective than diet alone for gestational diabetes mellitus (GDM). This approach helps identify biomarkers to monitor treatment benefits in GDM patients.

Area of Science:

  • Metabolic diseases
  • Genomics
  • Maternal-fetal medicine

Background:

  • Metabolic diseases like gestational diabetes mellitus (GDM) are typically assessed by single parameters.
  • Gene expression profiling offers a multidimensional approach to understanding disease states and treatment responses.

Purpose of the Study:

  • To investigate gene expression profiles in maternal tissues and placentas of normal and GDM patients.
  • To compare the effects of diet versus diet plus insulin therapy on gene expression in GDM.
  • To identify potential serum biomarkers for monitoring GDM treatment efficacy.

Main Methods:

  • Gene expression analysis was performed on four maternal tissues and placentas.
  • Samples were obtained from normal and euglycemic GDM patients undergoing Cesarean sections.
  • Patients were treated with either diet alone or diet plus insulin.

Main Results:

  • Gene expression deviations from normal were significantly greater (11-fold) in GDM patients treated with diet alone compared to those treated with diet plus insulin.
  • Insulin treatment resulted in gene expression profiles closer to normal, alongside euglycemia.

Conclusions:

  • Insulin therapy demonstrates a beneficial effect in achieving normal gene expression profiles and euglycemia in GDM treatment.
  • Gene expression data can guide the identification of serum biomarkers to monitor the benefits of insulin therapy in GDM.

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...